Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Cancer Risk
100%
Denmark
100%
Emulated Trial
100%
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs)
100%
GLP-1 Agonists
100%
Dipeptidyl peptidase-4 (DPP-4)
60%
Hazard Ratio
40%
Prior Cancer
40%
Body Mass Index
20%
Register-based
20%
Risk of Death
20%
Composite Outcome
20%
Danes
20%
Receptor Agonist
20%
Glucagon-like
20%
Patient Characteristics
20%
Survival Benefit
20%
Long-term Clinical Study
20%
Baseline Characteristics
20%
Initiating Treatment
20%
Residual Confounding
20%
Risk Difference
20%
Propensity Score Matching
20%
Long-term Observational Study
20%
Excess Lifetime Cancer Risk
20%
G-computation
20%
Sustained Use
20%
1 Receptor
20%
Cancer Societies
20%
Sex-stratified
20%
Scientific Committee
20%
Medicine and Dentistry
Malignant Neoplasm
100%
Glucagon-Like Peptide-1 Agonist
100%
Dipeptidyl Peptidase-4 Inhibitor
30%
Hazard Ratio
20%
Observational Study
10%
Body Mass Index
10%
Patient Characteristics
10%
Clinical Study
10%
Attributable Risk
10%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Dipeptidyl Peptidase IV Inhibitor
30%
Observational Study
10%
Clinical Study
10%